Meet Dr. Robert D. Mitchell – NorthEast Neurology and CHS Neurosciences Institute

|Meet Dr. Robert D. Mitchell – NorthEast Neurology and CHS Neurosciences Institute

Meet Dr. Robert D. Mitchell – NorthEast Neurology and CHS Neurosciences Institute

 

Dr. Robert D. Mitchell has been with Carolinas HealthCare System NorthEast for 30 years. He currently serves as Medical Director of NorthEast Neurology and Associate Medical Director of Carolinas Healthcare System Neurosciences Institute.  In addition to his clinical responsibilities as a neurologist, Dr. Mitchell has served as a clinical assistant professor of neurology at Duke University Medical Center since 1988.

Dr. Mitchell is a graduate of Vanderbilt University and received his Doctor of Medicine from the University of Michigan Medical School. He completed residencies in both Internal Medicine and Neurology at the University of Cincinnati Medical Center. He is certified by the American Board of Psychiatry and Neurology, as well as the American Board of Internal Medicine.  He and his family moved to Concord in June of 1988 when he joined the H&M Medical Clinic.  He was the only neurologist in Concord for seven years.

Dr. Mitchell has served in a variety of leadership roles during his career at Carolinas HealthCare System NorthEast and continues to be a leader as an administrator and a clinician. He serves on CHS Committees for the Neuroscience Institute, Adult Acute Care and Academics and Research. He has most recently served as principal investigator of the TOMMORROW Study.  CHS Northeast is one of about 50 sites worldwide completing the TOMMORROW Study, a first of a kind Alzheimer’s Disease trial to validate a genomic biomarker which will hopefully predict the risk of the onset of mild cognitive impairment(MCI) due to Alzheimer’s Disease. The Northeast site has one of the highest retention rates in the study in large part due to the diligence of the TOMMORROW staff (Sabrina Smith RN Study Coordinator, Vicki Cooke RN assisting Sabrina) and conscientious qualities of the participants in our region.  Another endpoint in the study was to assess whether a low dose of a common diabetes medication, pioglitazone, could delay onset of MCI but the study was unable to confirm the endpoint.

Dr. Mitchell and his wife, Karen, are longtime supporters of NorthEast Foundation. They have contributed to the foundation’s capital campaigns for over 20 years.  We are so thankful for the work Dr. Mitchell does at the Neurosciences Institute at CHS NorthEast.  He is a well-respected physician in our community and we are grateful for the compassionate care he provides to the patients in our community.

By |2018-06-18T12:05:20+00:00May 16th, 2018|Press Releases|0 Comments

About the Author:

Leave A Comment